Partnerships

Building Strategic Partnerships to Advance Cancer Research and Improve Patient Outcomes

Strategy

Partnering for 
Breakthrough Therapies

We collaborate with forward-thinking partners to pioneer the next generation of antibody-based therapeutics. By combining our strengths, we deepen our understanding of the cancer synapse to overcome the challenges of drug development, with the shared goal of combatting cancer. Together, we are committed to making a meaningful impact on global health.
2partnered clinical assets
6active collaborations
7partnered pre-clinical assets

Our Partnership Approach

We have a strong history of successful partnerships with leading pharmaceutical companies. We seek strategic partnerships that focus on advancing patient care through the development of antibody-based therapeutics. To explore ways in which we could help you achieve your oncology development goals, please contact us.
Get in Touch

Current Collaborations

We are proud to collaborate with several leading companies and institutions in the oncology field, working together to accelerate the development of groundbreaking oncology therapies.
Partnered Programs

Immunogen

In June 2022, OBT entered into a research collaboration with ImmunoGen to develop novel Antibody-Drug Conjugates (ADCs) targeting cancers with high unmet needs. This partnership leverages ImmunoGen’s advanced linker-payload technology and our proprietary OGAP® discovery platform to identify novel targets.